about
Inflammation-induced acute phase response in skeletal muscle and critical illness myopathyExtracorporeal lung support in H1N1 provoked acute respiratory failure: the experience of the German ARDS NetworkCharacteristics and provision of care of patients with the acute respiratory distress syndrome: descriptive findings from the DACAPO cohort baseline and comparison with international findings.Outcome of acute respiratory distress syndrome in university and non-university hospitals in GermanyRisk factors in critical illness myopathy during the early course of critical illness: a prospective observational study.The E3 ubiquitin ligase TRIM62 and inflammation-induced skeletal muscle atrophy.Intensive care unit-acquired weakness (ICUAW) and muscle wasting in critically ill patients with severe sepsis and septic shockSocial support during intensive care unit stay might improve mental impairment and consequently health-related quality of life in survivors of severe acute respiratory distress syndromeInfluence of quality of care and individual patient characteristics on quality of life and return to work in survivors of the acute respiratory distress syndrome: protocol for a prospective, observational, multi-centre patient cohort study (DACAPO).Predictors of survival in critically ill patients with acute respiratory distress syndrome (ARDS): an observational studyS2e guideline: positioning and early mobilisation in prophylaxis or therapy of pulmonary disorders : Revision 2015: S2e guideline of the German Society of Anaesthesiology and Intensive Care Medicine (DGAI).Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-studyCARbon DIoxide for the treatment of Febrile seizures: rationale, feasibility, and design of the CARDIF-study.Accuracy, reliability, feasibility and nurse acceptance of a subcutaneous continuous glucose management system in critically ill patients: a prospective clinical trial.Evidence-based therapy of severe acute respiratory distress syndrome: an algorithm-guided approach.Whole-body vibration to prevent intensive care unit-acquired weakness: safety, feasibility, and metabolic response.Weaning from mechanical ventilation and sedation.Efficacy and safety of argatroban in patients with acute respiratory distress syndrome and extracorporeal lung support.Measuring Energy Expenditure in extracorporeal lung support Patients (MEEP) - Protocol, feasibility and pilot trial.Adjunctive therapies in severe sepsis and septic shock: current place of steroids.(13) C Breath Tests Are Feasible in Patients With Extracorporeal Membrane Oxygenation Devices.S2k-Guideline "Prolonged Weaning".Bolus or continuous hydrocortisone--that is the questionInfluenza A (H1N1) vs non-H1N1 ARDS: analysis of clinical course.The BREATHE-appeal: harmonize interaction between patient and ventilator!Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness.Critical illness polyneuropathy in ICU patients is related to reduced motor nerve excitability caused by reduced sodium permeability.Critical illness myopathy and GLUT4: significance of insulin and muscle contraction.Propagation of cortical spreading depolarization in the human cortex after malignant stroke.Critical illness myopathy is frequent: accompanying neuropathy protracts ICU discharge.Critical illness polyneuropathy and myopathy in patients with acute respiratory distress syndrome.[Weaning--sounds simple, but it is not!].Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients.Glycemic variability as a risk factor of intensive care unit-acquired weakness.Hyperactive delirium and blood glucose control in critically ill patients.Bronchial fistulae in ARDS patients: management with an extracorporeal lung assist device.Long-term outcome after the acute respiratory distress syndrome: different from general critical illness?Gastrointestinal zygomycosis caused by Mucor indicus in a patient with acute traumatic brain injury.Early type II fiber atrophy in intensive care unit patients with nonexcitable muscle membrane.Secreted Frizzled-Related Protein 2 and Inflammation-Induced Skeletal Muscle Atrophy.
P50
Q27314918-DB3A9DA9-30ED-4C06-976E-90DC6CB80907Q30353915-FC6E6D06-CA7B-49F0-A862-257B9EAA8010Q33571332-FBD5DF5D-59E3-417C-AAA3-286903E0B34DQ33737754-B613955D-D010-432F-9FF2-60680FFE84D3Q34027050-0C54FAB1-F3C8-4596-A13A-321C798C76BFQ34507052-6E1C8E77-2696-499E-A193-506FFCE94B62Q34697264-97F66152-E906-4B10-B9B4-852D3C1E424CQ35544758-6CCCCBFF-3385-49C7-BB57-49747FF0A8BEQ35871515-C66C63DC-C665-4391-97DD-59FB9F905DEDQ36184568-0634512A-D905-4F82-B137-F8E17DE71921Q36460488-E1426F57-4C17-4B82-B6AB-0C4BECF65E21Q36762900-C215CFA7-26F6-4A8A-AE79-14BB3CCB0F5DQ36980537-5A70F1FB-E25A-4295-A89F-15076A200FBAQ37112346-AC8A9E03-61B2-4C53-8A72-68B7D0FEAE9EQ37124985-29A2F341-04C2-4EF2-9EBB-53901704C7ADQ37572090-6FB36662-B60D-4029-84C8-CF47A9BF813CQ37975945-FC56B113-77EF-488B-9478-703BEEBA60B6Q38641761-0B5DDF72-CE87-40E0-AC4B-1BE4077E48E5Q38988350-72ACE20E-FD3F-4A27-9640-C894952AACCDQ40061923-A62131EE-1928-489E-824E-A88DFB82F40FQ40363616-BD553ABD-B671-4B17-A1D6-F625760C946DQ41253796-AC5D375F-2536-46D8-BC41-748C28CDDBEEQ42113256-61587A3B-E430-4DCC-87CE-A73E9368C691Q42229282-E65918B8-1F77-4F8E-86E8-9EC2C9F00F32Q42331421-EF40E28A-DCC2-47D7-A59D-8F63A6AA5520Q42643598-6254EEE5-2854-4C3C-B1D5-BCD8CD81462EQ42771439-412BB51D-F190-4689-B86C-4D040B58B108Q43483723-D4764612-191B-4620-A697-FFCA33488351Q43808516-FAE18610-3688-4A7C-82C0-D3C2068C2569Q43977687-4918098E-275A-4440-8F79-99EBA713828FQ44285084-9654A4F6-AC49-425F-B14F-6EA3E7F3152DQ44759815-03491B5E-BC98-4724-82AD-D3C33220CC1CQ44818083-E3006FBE-BCA3-4A91-8336-5C0D01CAA117Q46446977-5F8598C0-9142-4CC1-AFAC-02B27F065355Q46978058-B992AC4A-4624-405B-B711-F42E65BB13B7Q47208463-37D5A6C5-5FAB-4FDF-AE61-5B111A5B2F0CQ47226052-E26DDEFE-9A50-49BE-9AE3-3F682F775640Q48384491-F6540781-3974-4B2D-9462-0356D2D13E4BQ51003894-A78029B9-AD10-44C3-8517-873AF66C04D4Q51470568-F7A1EBFD-1EA6-47FE-A03D-CEC388AC8BFB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Steffen Weber-Carstens
@ast
Steffen Weber-Carstens
@en
Steffen Weber-Carstens
@es
Steffen Weber-Carstens
@nl
Steffen Weber-Carstens
@sl
type
label
Steffen Weber-Carstens
@ast
Steffen Weber-Carstens
@en
Steffen Weber-Carstens
@es
Steffen Weber-Carstens
@nl
Steffen Weber-Carstens
@sl
prefLabel
Steffen Weber-Carstens
@ast
Steffen Weber-Carstens
@en
Steffen Weber-Carstens
@es
Steffen Weber-Carstens
@nl
Steffen Weber-Carstens
@sl
P214
P106
P1153
16064817400
P214
P31
P496
0000-0001-7405-0172
P5008
P7859
viaf-77240941